570P Feasibility and biomarker validation of an international randomized phase 3 trial of bria-IMT cell therapy in late stage MBC (Bria-ABC)
Year: 2025
Type: article
Source: Annals of Oncology
Authors: S. Hurvitz, J. O'Shaughnessy, C. Nangia, L. Negret, C. CALFA, A. Kahn, M. Barve, R. Shatsky, A. Brufsky, R. Zuniga, M. Cristofanilli, B. Bayer, W. Williams, G. Del Priore, S. Chumsri
Institutions: University of Washington, Hoag Memorial Hospital Presbyterian, University of Miami, Sylvester Comprehensive Cancer Center, Yale University, Mary Crowley Cancer Research Center, UC San Diego Health System, Moores Cancer Center, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Morehouse School of Medicine, Mayo Clinic in Florida
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4415941893